Citations

Clear

3030 citation(s) found for "Susan, M".

TMOD-07. LOCALIZATION OF ERLOTONIB RELATIVE TO MRI-BASED TUMOR EXTENT IN PDX GLIOBLASTOMA MODEL: TOWARDS A MATHEMATICAL MODEL FOR THE INTERFACE BETWEEN MRI AND DRUG DISTRIBUTION
Jackson, Pamela , Ranjbar, Sara , Randall, Elizabeth C., Lopez, Begona, Hu, Leland , Regan, Michael S. , Abdelmoula, Walid M. , Lopez, Begona, Massey, Susan Christine , He, Lihong , Macura, Slobodan , Agar, Jeffrey N. , Sarkaria, Jann N. , Agar, Nathalie Y.R. , Swanson, Kristin R

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi269-vi270

10.1093/neuonc/noy148.1120 Get It

Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)
Kutny, Matthew A. , Geyer, Susan, Laumann, Kristina, Gregory, John , Powell, Bayard L., Feusner, James H., Laumann, Kristina M, Willman, Cheryl L. , Stock, Wendy , Larson, Richard A.

Mayo Clinic

Pediatric Blood & Cancer | November 5, 2018 | Volume: 66 | Issue: 3 | Pages: No page available

10.1002/pbc.27542 | PMID 30393935 Get It

AbstractBackgroundAcute promyelocytic leukemia (APL) is a unique leukemia subtype requiring specialized treatment including all‐trans retinoic acid (ATRA). A prior report demonstrated worse outcome among young children <5 years old compared with older children.MethodsWe evaluated outcomes for pediatric patients (<18 years old; N = 83) with APL treated on North American intergroup study CALGB 9710 at Children's Oncology Group sites. Induction and consolidation included ATRA, cytarabine, and anthracyclines. Patients ≥15 years old were randomized to addition of arsenic trioxide (ATO) consolidation. All patients were randomized to ATRA maintenance with versus without oral chemotherapy.ResultsThe estimated 5‐year overall survival (OS) rate was 82%, and the event‐free survival (EFS) rate was 54%. Seven patients (8.4%) died during induction due to coagulopathy. Maintenance randomization demonstrated that addition of oral chemotherapy to ATRA significantly reduced relapse rate, but difference in EFS did not reach statistical significance (P = 0.12; 5‐year rates [95% CI]: 41% [17%–64%] ATRA only vs 72% [56%–88%] ATRA plus chemotherapy). There was no difference (P = 0.93) in EFS for age <5 years versus 5–12.99 years versus 13–17.99 years (5‐year rates: 56%, 47%, and 45%, respectively). Among adolescents 15–17.99 years old in the ATO randomization, there was a significantly lower relapse risk at 5 years for those receiving ATO (0% ATO vs 44% no ATO; P = 0.02).ConclusionOur data demonstrate that intensified ATRA, cytarabine, and anthracycline chemotherapy is effective for pediatric APL including very young patients, but early deaths and relapses remain barriers to cure. Further improvements are likely with incorporation of ATO into pediatric APL regimens.
Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder
Behrendt‐møller, Ida , Madsen, Trine , Sørensen, Holger J. , Sylvia, Louisa G. , Friedman, Edward S., Shelton, Richard C. , Bowden, Charles L., Calabrese, Joseph R. , Ketter, Terence A. , Reilly-Harrington, Noreen A. , Gao, Keming , Thase, Michael E., Tohen, Mauricio , McInnis, Melvin G. , Kamali, Masoud , Kocsis, James H., Deckersbach, Thilo , Nierenberg, Andrew A. , Ketter, Terence A , Gao, Keming , V Bobo, William , Tohen, Mauricio , Kamali, Masoud , McInnis, Melvin G , McElroy, Susan L. , Bobo, William V. , Köhler‐Forsberg, Ole

Mayo Clinic

Bipolar Disorders | November 1, 2018 | Volume: 21 | Issue: 4 | Pages: 350-360

10.1111/bdi.12715 | PMID 30383333 Get It

IntroductionDepressive episodes are often prevalent among patients with bipolar disorder, but little is known regarding the differential patterns of development over time. We aimed to determine and characterize trajectories of depressive symptoms among adults with bipolar disorder during 6 months of systematic treatment.MethodsThe pragmatic clinical trial, Bipolar Clinical Health Outcomes Initiative in Comparative Effectiveness (CHOICE), randomized 482 outpatients with bipolar disorder to lithium or quetiapine. Depressive symptoms were rated at up to 9 visits using the Montgomery‐Asberg Depression Rating Scale (MADRS). Growth mixture modeling was utilized to identify trajectories and multinomial regression analysis estimated associations with potential predictors.ResultsFour distinct trajectories of depressive symptoms were identified. The responding class (60.3%) with a rapid reduction and subsequent low level; the partial‐responding class (18.4%) with an initial reduction followed by an increase during the remaining weeks; the fluctuating class (11.6%) with a fluctuation in depressive symptoms; and the non‐responding class (9.7%) with sustained moderate‐severe depressive symptoms. Bipolar type I predicted membership of the non‐responding class and randomization to quetiapine predicted membership of either the responding or the non‐responding class.ConclusionApproximately 30% experienced a partial or fluctuating course, and almost 10% had a chronic course with moderate‐severe depression during 6 months. Patients diagnosed with bipolar type 1 had higher risk of being categorized into a class with a worse outcome. While no differences in average overall outcomes occurred between the lithium and quetiapine groups, trajectory analysis revealed that the lithium group had more variable courses.
Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients
Woolley, Susan , Goetz, Ray, Factor‐Litvak, Pam , Murphy, Jennifer , Hupf, Jonathan , Lomen‐Hoerth, Catherine , Andrews, Howard , Heitzman, Daragh, Bedlack, Richard , Katz, Jonathan, Barohn, Richard J., Sorenson, Eric J. , Oskarsson, Björn , Filho, Americo Fernandes, Kasarskis, Edward J. , Mozaffar, Tahseen , Nations, Sharon , Swenson, Andrea , Koczon-Jaremko, Agnes, Christodoulou, Georgia , Mitsumoto, Hiroshi , Garofalo, Diana C. , Sorenson, Eric, Oskarsson, Björn , Bedlack, Richard S , Christodoulou, Georgia

Mayo Clinic

Behavioural Neurology | October 31, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-7

10.1155/2018/5969137 | PMID 30515252 Get It

Objective. To evaluate longitudinal cognitive/behavioral change over 12 months in participants enrolled in the ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS). Methods. We analyzed data from 294 ALS participants, 134 of whom were studied serially. Change over time was evaluated controlling for age, sex, symptom duration, education, race, and ethnicity. Using multiple regression, we evaluated associations among decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores, forced vital capacity (FVC), and cognitive/behavioral changes. Change in cognitive/behavioral subgroups was assessed using one-way analyses of covariance. Results. Participants with follow-up data had fewer baseline behavior problems compared to patients without follow-up data. We found significant worsening of behavior (ALS Cognitive Behavioral Screen (ALS CBS) behavioral scale, p<0.001; Frontal Behavioral Inventory-ALS (FBI-ALS) disinhibition subscale, p=0.044). Item analysis suggested change in frustration tolerance, insight, mental rigidity, and interests (p<0.05). Changes in ALSFRS-R correlated with the ALS CBS. Worsening disinhibition (FBI-ALS) did not correlate with ALSFRS-R, FVC, or disease duration. Conclusion. We did not detect cognitive change. Behavioral change was detected, and increased disinhibition was found among patients with abnormal baseline behavioral scores. Disinhibition changes did not correlate with disease duration or progression. Baseline behavioral problems were associated with advanced, rapidly progressive disease and study attrition.
Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
Adams, Charleen D. , Richmond, Rebecca C. , Ferreira, Diana L. Santos , Spiller, Wes , Tan, Vanessa Y. , Würtz, Peter , Donovan, Jenny , Hamdy, Freddie C. , Neal, David E. , Lane, J. Athene , Smith, George Davey , Relton, Caroline L. , Eeles, Rosalind A. , Haiman, Christopher A. , Schumacher, Fredrick R. , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Berndt, Sonja I., Conti, David V. , Gapstur, Susan M. , Stevens, Victoria L. , Batra, Jyotsna , Grönberg, Henrik , Pashayan, Nora , Schleutker, Johanna , West, Catharine , Mucci, Lorelei A. , Koutros, Stella , Sørensen, Karina D. , Mæhle, Lovise, Travis, Ruth C. , Rosenstein, Barry S. , Lu, Yong‐Jie , Kibel, Adam S. , Vega, Ana , Stanford, Janet L. , Nordestgaard, Børge G. , Maier, Christiane, Kim, Jeri , John, Esther M. , Teixeira, Manuel R. , Newcomb, Lisa F., Lessel, Davor , Kaneva, Radka , Usmani, Nawaid , Claessens, Frank , Townsend, Paul A. , Dominguez, Manuela Gago, Roobol, Monique J. , Ménégaux, F. , Pandha, Hardev , Thibodeau, Stephen N. , Martin, Richard M. , Teixeira, Manuel R , Vega, Ana , Eeles, Rosalind A , John, Esther M , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Lessel, Davor , Koutros, Stella , Martin, Richard M , Conti, David V , Batra, Jyotsna , Davey Smith, George , Zheng, Jie , Kote‐Jarai, Zsofia , Berndt, Sonja I. , Wiklund, Fredrik E. , Chanock, Stephen Jacob , Tangen, Catherine M. , Clements, Judith A. , Albanes, Demetrius , Wolk, Alicja , Cancel‐Tassin, Géraldine , Hamilton, Robert J , Ingles, Sue A. , Giles, Graham G. , Kogevinas, Manolis , Penney, Kathryn , Park, Jong Y. , Cybulski, Cezary , Brenner, Hermann , Neuhausen, Susan L. , Ruyck, Kim De , Razack, Azad Hassan Abdul , Khaw, Kay‐Tee , Cannon‐Albright, Lisa , Claessens, Frank

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 23, 2018 | Volume: 28 | Issue: 1 | Pages: 208-216

10.1158/1055-9965.epi-18-0079 | PMID 30352818 Get It

Abstract Background: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise causality for a subset of the prostate cancer–metabolite associations using two-sample Mendelian randomization (MR). Methods: The case–control portion of the study was conducted in nine UK centers with men ages 50–69 years who underwent prostate-specific antigen screening for prostate cancer within the Prostate Testing for Cancer and Treatment (ProtecT) trial. Two data sources were used to appraise causality: a genome-wide association study (GWAS) of metabolites in 24,925 participants and a GWAS of prostate cancer in 44,825 cases and 27,904 controls within the Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. Results: Thirty-five metabolites were strongly associated with prostate cancer (P &lt; 0.0014, multiple-testing threshold). These fell into four classes: (i) lipids and lipoprotein subclass characteristics (total cholesterol and ratios, cholesterol esters and ratios, free cholesterol and ratios, phospholipids and ratios, and triglyceride ratios); (ii) fatty acids and ratios; (iii) amino acids; (iv) and fluid balance. Fourteen top metabolites were proxied by genetic variables, but MR indicated these were not causal. Conclusions: We identified 35 circulating metabolites associated with prostate cancer presence, but found no evidence of causality for those 14 testable with MR. Thus, the 14 MR-tested metabolites are unlikely to be mechanistically important in prostate cancer risk. Impact: The metabolome provides a promising set of biomarkers that may aid prostate cancer classification.
P4‐288: DETAILS OF THE NEW ALZHEIMER'S ASSOCIATION BEST CLINICAL PRACTICE GUIDELINES FOR THE EVALUATION OF NEURODEGENERATIVE COGNITIVE BEHAVIORAL SYNDROMES, ALZHEIMER'S DISEASE AND DEMENTIAS IN THE UNITED STATES
Norman, Mary S., Karlawish, Jason , Sano, Mary , Onyike, Chiadi U. , Lin, Paige E. , Clevenger, Carolyn , Scanland, Susan, Hendrix, James A. , Dickerson, Brad C., Atri, Alireza , Knopman, David S. , Norman, Mary, Lin, Paige, Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_30 | Pages: No page available

10.1016/j.jalz.2018.07.110 Get It

F4‐06‐01: TIMING AND TRAJECTORY OF ESTABLISHED MECHANISMS: AMYLOID β AND TAU DEPOSITION, AND NEURODEGENERATION
Margolin, Richard , Landau, Susan, Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_26 | Pages: No page available

10.1016/j.jalz.2018.06.2884 Get It

O1‐02‐03: DIAN‐TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA
Santacruz, Anna , Farlow, Martin R. , Salloway, Stephen , Fagan, Anne M. , Wang, Guoqiao , Koeppe, Bob, Martényi, Ferenc, Yaari, R. , Siemers, Eric , Clifford, David B. , Bateman, Randall J. , Mills, Susan, Morris, John C. , Benzinger, Tammie L.S. , Goate, Alison , Hassenstab, Jason , Xiong, Chengjie , Jack, Clifford R. , Searle, Alison, McDade, Eric

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2018.06.2338 Get It

P3‐378: EFFECT OF AGE, GENDER, ETHNICITY, COGNITION AND APOE GENOTYPE ON AMYLOID LOAD AMONG NORMAL, MCI AND MILD DEMENTIA SUBJECTS USING [F‐18] FLORBETABEN
Duara, Ranjan , Lizarraga, Gabriel , Adjouadi, Malek , Barker, Warren , Greig‐Custo, Maria T., Peñate, Ailyn, Hanson, Kevin , Ertekin‐Taner, Nilüfer , Vaillancourt, David E. , Santi, Susan De , Golde, Todd E. , Duara, Ranjan , Loewenstein, David , Marsiske, Michael , Burke, Shanna L. , DeKosky, Steven T.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_23 | Pages: No page available

10.1016/j.jalz.2018.06.1740 Get It